| Segment Reporting |
Significant segment expenses, as provided to the CODM are as follows:
| | | | | | | | | |
|
|
|
|
|
| |
|
Three Months
Ended March 31,
|
| |
|
2025
|
|
2024
|
|
Sales
|
|
$ |
341,264 |
|
|
|
271,140 |
|
|
Cost of sales (excluding depreciation expense)
|
|
|
117,266 |
|
|
|
88,532 |
|
| |
|
| | |
|
| | |
|
Research and development expense
|
|
|
959,162 |
|
|
|
415,263 |
|
|
Other research and development expenses1
|
|
|
2,009,310 |
|
|
|
1,355,468 |
|
|
Total research and development expense
|
|
|
2,968,472 |
|
|
|
1,770,731 |
|
| |
|
| | |
|
| | |
|
Sales and marketing
|
|
|
908,567 |
|
|
|
300,487 |
|
|
General and administrative
|
|
|
1,722,713 |
|
|
|
1,502,804 |
|
|
Depreciation and amortization expense
|
|
|
84,853 |
|
|
|
71,228 |
|
|
Total operating expenses
|
|
|
5,684,605 |
|
|
|
3,645,250 |
|
| |
|
| | |
|
| | |
|
Total other (expense) income, net
|
|
|
(440,420 |
) |
|
|
(136,868 |
) |
|
Loss before income taxes
|
|
|
(5,901,027 |
) |
|
|
(3,599,510 |
) |
|
Income tax (benefit)
|
|
|
(4,188 |
) |
|
|
— |
|
|
Net loss
|
|
$ |
(5,896,839 |
) |
|
|
(3,599,510 |
) |
1 Other
research and development expenses include clinical affairs, regulatory,
manufacturing and quality assurance expenses.
|